Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial (PreNATUS)
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- Natera, Inc.
- 入组人数
- 937
- 试验地点
- 29
- 主要终点
- Sensitivity and Specificity of the test to diagnose aneuploidy in a fetus at chromosomes 13, 18, 21, X and Y.
研究概览
简要总结
This prospective blinded study will assess the diagnostic capability of an informatics enhanced SNP based technology (Parental Support) to identify pregnant women who are carrying a fetus with an aneuploidy from fee floating DNA in the maternal blood.
详细描述
First trimester screening is the current standard of care for pregnant women in the United States. Women with a high screening risk for trisomy then have invasive testing, which carries a risk of miscarriage, to definitively determine if the fetus has trisomy. Because of the high false negative rate of the first trimester screening, an unacceptable number of trisomic fetuses are not detected. Moreover, because of the high false positive rate, an unacceptable number of women undergo invasive follow up testing. Additional screening tests are needed that combine a high sensitivity, a low false positive rate, and minimal or no risk to the fetus.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Singleton pregnancy
- •Gestational age between 8 weeks 0 days and 23 weeks, 6 days by best obstetrical estimate
- •Mother has a high or moderate risk for trisomy
- •Mother is planning to have or has had an amniocentesis or chorionic villus sampling (CVS) procedure
排除标准
- •Unavailability of the father to provide a genetic sample (e.g. sperm donor, non-paternity)
- •Egg donor used
- •Mother or father have known chromosomal abnormalities (including known balanced translocations)
- •Participation in the study in a previous pregnancy
- •Pregnancy is a result of IVF with pre-implantation genetic diagnosis
结局指标
主要结局
Sensitivity and Specificity of the test to diagnose aneuploidy in a fetus at chromosomes 13, 18, 21, X and Y.
时间窗: Between first trimester screening (10-14 weeks GA) and invasive testing (amniocentesis or CVS).
The primary objective is to determine the diagnostic capability of the test to detect autosomal aneuploidy (chromosomes 13, 18, 21) and sex aneuploidy (X and Y).
次要结局
未报告次要终点
